Objectif The need: Today, although over 6M people suffer from Parkinson's and related diseases worldwide we have no objective early diagnostic test. By the time patients present the symptoms that lead to diagnosis the disease is already very advanced and the options for treatment extremely limited. This has an enormous impact on cost of care and an even greater impact on patient and carer quality of life. An early diagnostic test will revolutionise treatment in terms of slowing disease evolution and improved outcomes, with fewer years in the advanced phases of the disease requiring expensive full-time care. Our goal: We aim to commercialise non-invasive, very low-cost preclinical electroencephalograph (EEG) biomarkers for synucleinopathies (Parkinson Disease - PD and Lewy Body Dementia - LBD), which will have real impact on both quality of life and cost of care. Champ scientifique social scienceseconomics and businessbusiness and managementbusiness modelsmedical and health sciencesbasic medicineneurologydementiamedical and health sciencesbasic medicineneurologyparkinson Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Thème(s) PHC-12-2014-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices Appel à propositions H2020-SMEInst-2014-2015 Voir d’autres projets de cet appel Sous appel H2020-SMEINST-1-2014 Régime de financement SME-1 - SME instrument phase 1 Coordinateur STARLAB BARCELONA SL Contribution nette de l'UE € 50 000,00 Adresse AVENIDA TIBIDABO 47 BIS 08035 Barcelona Espagne Voir sur la carte PME L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention. Oui Région Este Cataluña Barcelona Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Liens Contacter l’organisation Opens in new window Site web Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 71 429,00
